Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 6.02 | -1.95% | -0.12 |
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Bollinger Band Squeeze | Range Contraction | -1.95% | |
NR7 | Range Contraction | -1.95% | |
NR7-2 | Range Contraction | -1.95% | |
Oversold Stochastic | Weakness | -1.95% | |
Bollinger Band Squeeze | Range Contraction | -1.47% | |
NR7 | Range Contraction | -1.47% | |
Doji - Bullish? | Reversal | -1.47% | |
Oversold Stochastic | Weakness | -1.47% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Up 2% | about 12 hours ago |
Down 2 % | about 14 hours ago |
Down 1% | about 14 hours ago |
Fell Below Previous Day's Low | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 03/21/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.1939 |
52 Week Low | 1.5735 |
Average Volume | 261,146 |
200-Day Moving Average | 3.54 |
50-Day Moving Average | 5.85 |
20-Day Moving Average | 6.73 |
10-Day Moving Average | 6.48 |
Average True Range | 0.54 |
RSI (14) | 45.36 |
ADX | 21.2 |
+DI | 17.79 |
-DI | 22.06 |
Chandelier Exit (Long, 3 ATRs) | 6.58 |
Chandelier Exit (Short, 3 ATRs) | 7.60 |
Upper Bollinger Bands | 7.65 |
Lower Bollinger Band | 5.81 |
Percent B (%b) | 0.11 |
BandWidth | 27.24 |
MACD Line | 0.08 |
MACD Signal Line | 0.26 |
MACD Histogram | -0.1799 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.46 | ||||
Resistance 3 (R3) | 6.50 | 6.39 | 6.39 | ||
Resistance 2 (R2) | 6.39 | 6.27 | 6.37 | 6.36 | |
Resistance 1 (R1) | 6.20 | 6.20 | 6.15 | 6.17 | 6.34 |
Pivot Point | 6.09 | 6.09 | 6.06 | 6.07 | 6.09 |
Support 1 (S1) | 5.91 | 5.98 | 5.85 | 5.87 | 5.70 |
Support 2 (S2) | 5.80 | 5.91 | 5.78 | 5.68 | |
Support 3 (S3) | 5.61 | 5.80 | 5.65 | ||
Support 4 (S4) | 5.58 |